Shifting Tides: Embracing Total Neoadjuvant Therapy for Advanced Rectal Cancer

Examining trends from 2012 to 2020, researchers unveil that over 50% of 51,407 patients with locally advanced rectal cancer received total neoadjuvant chemoradiation (TNT). Factors like age and comorbidities influenced TNT rates, with stage III patients more likely to undergo it. Notably, TNT usage increased by 38% post-guideline inclusion in 2018. This study not only captures evolving treatment patterns but also establishes a benchmark for future assessments, reflecting a substantial adoption of TNT in rectal cancer care.